This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein: Amarin's Sloooow Vascepa Launch

BEDMINSTER, NJ ( TheStreet) -- The early verdict on Amarin's (AMRN) Vascepa launch: Slow.

Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its prescription-grade fish oil pill. But right now, weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected.

Amarin shares fell 3.5% to $7.36 in Monday trading. The stock is trading just slightly higher than its 52-week low of $7.30 -- a reflection of investor concern about the trajectory of the Vascepa launch.

Let's take a look at the prescription numbers, according to IMS Health. The latest figures are for the week ended March 15.

Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15.

There is no "right" rate of growth for a new drug launch but this early, investors definitely want to see accelerating script growth. Deceleration at this stage of the launch is an uneasy sign. Amarin is offering incentives to doctors and patients in the form of free Vascepa samples and discounts, which is likely affecting script numbers. How much can't be quantified.

Refill rates can only be estimated from weekly IMS data, but again, the numbers don't work in Amarin's favor.

For the week of Feb 15 (still really early in the launch), total (560) and new (555) Vascepa scripts were essentially the same. This means just about every patient was new on Vascepa. Fast forward one month to March 15. At this point, patients prescribed Vascepa in mid-February should be going back to their pharmacy for another bottle, so ideally, the the difference between total and new prescriptions should be close to 500 for the week of March 15.

The actual difference between total and new Vascepa scripts for March 15 is 141, suggesting a good number of patients didn't come back for a refill.

Amarin was forced to launch Vascepa on its own in late January after a marketing partner failed to materialize.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.85 0.00%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs